Skip to content
Search

Latest Stories

Scottish firm to trial T cells as possible Covid-19 treatment

A Scottish biotechnology firm said on Tuesday (June 30) it would start clinical trials on a possible T cell treatment for Covid-19, aimed at reducing the need for intensive care among hospitalised patients.

T cells are white blood cells that form a key part of the immune system, along with antibodies, and scientists are hopeful they could play a role in tackling the novel coronavirus pandemic.


TC BioPharm (TCB) said it would conduct the trial at the Edinburgh Royal Infirmary, using gamma-delta T cells in a technique it has previously used on cancer patients.

"Harnessing the immune system to effectively and safely kill virus-infected cells is an extremely attractive strategy," said Nik Hirani of the University of Edinburgh, the chief investigator for the trial.

The organisers of the trial said that data showed severely affected Covid-19 patients might have a deficiency of T cells.

TCB will manufacture banks of T cells, which can be donated by healthy volunteers, that it is then hoped can be used to treat patients as they develop severe Covid-19 symptoms.

Scottish Government Trade Minister Ivan McKee said in a statement that the devolved administration would support TC Biopharm and others in the attempt to develop treatments for Covid-19.

There is a global need to find safe and effective treatments for the disease, which has killed hundreds of thousands and severely hit most major economies in the six months since it was first discovered.

Steroid drug dexamethasone has been shown in a UK trial to reduce mortality in patients who need ventilation or oxygen, but not in those who are not yet severely ill, while Gilead's antiviral remdesivir is thought to be more effective in treating people earlier in the course of the disease.

(Reuters)

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less